Aligos Therapeutics, Inc. Common Stock vs. Repligen Corp
Repligen Corp (RGEN) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| ALGS | RGEN | |
|---|---|---|
| Market Cap | $45.46 million | $9.21 billion |
| Revenue (TTM) | — | $785.10 million |
| Net Income (TTM) | — | $41.54 million |
RGEN leads on 1 of 1 size & scale factors.
Valuation
| ALGS | RGEN | |
|---|---|---|
| P/E Ratio | — | 225.71 |
| Price / Book | — | 4.36 |
| Price / Sales | — | 11.73 |
ALGS and RGEN split the valuation factors evenly.
Profitability
| ALGS | RGEN | |
|---|---|---|
| Net Margin | — | 5.29% |
| Return on Equity | — | 1.97% |
ALGS and RGEN split the profitability factors evenly.
Risk & Sentiment
| ALGS | RGEN | |
|---|---|---|
| Short Interest | 36.27% | 7.13% |
RGEN leads on 1 of 1 risk & sentiment factors.
Dig deeper: ALGS overview, ALGS financials, RGEN overview, RGEN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.